BET bromodomain antagonist
Catalog No. B17-905B
|Catalog No.||Pack Size||Price (USD)|
RVX-208 also knows as Apabetalone is a potent selective inhibitor of the BET bromodomains. The compound has been thoroughly studied for its role against some key viruses such as HIV-1. By interacting with key bromodomain proteins BRD2 and BRD4, RVX-208 may inhibit the interaction of these proteins with the SARS-CoV-2 protein E, aiding in stopping some key viral processes such as cell entry and replication.**
RVX-208 is a potent BET bromodomain antagonist with IC50 of 0.510 µM for BD2, with approximately 170-fold selectivity over BD1 (1,2). Increases apolipoprotein A-1 and HDL cholesterol in vitro and in vivo (3). Reduces atherosclerosis (4).
1. S Picaud et al. Proc. Natl. Acad. Sci. USA 2013 110: 19754
2. KG McLure et al. PLoS One 2013 8:e83190
3. D Bailey et al. J. Am. Coll. Cardiol. 2010 55:2580
4. R Jahagirdar et al. Atherosclerosis 2014 236:91
CAS Registry Number:
>98% (TLC); NMR (conforms)
May be dissolved in DMSO (75 mg/ml); or ethanol (4 mg/ml)
Storage and Stability:
Store desiccated as supplied at -20°C for up to 2 years. Store solutions at -20°C for up to 1 month.
There are no related publications available for this product.